Journal
PHARMACEUTICS
Volume 14, Issue 6, Pages -Publisher
MDPI
DOI: 10.3390/pharmaceutics14061274
Keywords
[Tc-99m]Tc-1-thio-D-glucose; single-photon emission computed tomography; lymphoma; Hodgkin's lymphoma; non-Hodgkin's lymphomas
Categories
Funding
- Ministry of Science and Higher Education of the Russian Federation [075-15-2019-1925]
Ask authors/readers for more resources
This study evaluated the safety, biodistribution, and dosimetry of [Tc-99m]Tc-TG in lymphoma patients, and found that it can be considered as an additional diagnostic method for imaging GLUT receptors in these patients.
Similar to [F-18]-FDG, [Tc-99m]Tc-1-thio-D-glucose ([Tc-99m]Tc-TG) also binds to GLUT receptors. The aim of this Phase I study was to evaluate the safety, biodistribution and dosimetry of [Tc-99m]Tc-TG. Twelve lymphoma patients were injected with 729 +/- 102 MBq [Tc-99m]Tc-TG. Whole-body planar imaging was performed in 10 patients at 2, 4, 6 and 24 h after injection. In all 12 patients, SPECT/CT (at 2 h) and SPECT (at 4 and 6 h) imaging was performed. Vital signs and possible side effects were monitored during imaging and up to 7 days after injection. [Tc-99m]Tc-TG injections were well-tolerated and no side effects or alterations in blood and urine analyses data were observed. The highest absorbed dose was in the kidneys and urinary bladder wall, followed by the adrenals, prostate, bone marrow, lungs, myocardium, ovaries, uterus, liver and gall bladder wall. [Tc-99m]Tc-TG SPECT/CT revealed foci of high activity uptake in the lymph nodes of all nine patients with known nodal lesions. Extranodal lesions were detected in all nine cases. In one patient, a lesion in the humerus head, which was not detected by CT, was visualized using [Tc-99m]Tc-TG. Potentially, [Tc-99m]Tc-TG can be considered as an additional diagnostic method for imaging GLUT receptors in lymphoma patients.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available